title: Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction.
abstract: Effects of enalapril on a canine model of atrial pacing-induced atrial fibrillation (AF) with rapid ventricular responses were determined.
  
  
  METHODS
  Four weeks of atrial rapid pacing was performed on twenty-four beagles pretreated with placebo (Group I, n = 14) or enalapril 1 mg/kg (Group II, n = 10). Atrial effective refractory period (ERP), P-wave width, duration of AF, and left ventricular ejection fraction (LVEF) were evaluated every week. AF cycle length was determined by spectral analyses of fibrillation waves. Quantitative analysis of histology was added.
  
  
  RESULTS
  After 4 weeks of pacing, P-wave width was longer in Group I than in Group II, and the duration of induced AF was significantly longer in Group I (59.6 +/- 66.3 seconds) than in Group II (3.6 +/- 3.4 seconds, P < 0.05). AF cycle length was longer in Group I than in Group II despite similar shortening of atrial ERP. Mean ventricular rate during rapid atrial pacing was not different between the two groups. LVEF similarly decreased in both groups. Interstitial fibrosis and expression of connexin43 was greater in Group I than in Group II (interstitial fibrosis, 9.2 +/- 8.4 versus 1.9 +/- 2.1%, P < 0.05; connexin43, 5.3 +/- 2.2 versus 1.1 +/- 1.1%, P < 0.05).
  
  
  CONCLUSIONS
  Enalapril suppressed atrial pacing-induced AF with tachycardia-mediated cardiomyopathy by suppressing interstitial fibrosis, connexin43 over-expression and conduction delay.
authors.affiliation: Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan.
authors.forename: Masao
authors.initials: M
authors.lastname: Sakabe
authors.forename: Akira
authors.initials: A
authors.lastname: Fujiki
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Nishida
authors.forename: Masataka
authors.initials: M
authors.lastname: Sugao
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Nagasawa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tsuneda
authors.forename: Koichi
authors.initials: K
authors.lastname: Mizumaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inoue
mesh_terms: D000818:Animals; D001281:Atrial Fibrillation / Q000473:pathology* / Q000503:physiopathology / Q000517:prevention & control*; D002304:Cardiac Pacing, Artificial; D018031:Connexin 43 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D004195:Disease Models, Animal; D004285:Dogs; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005355:Fibrosis; D008297:Male; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D018031:Connexin 43; D004656:Enalapril